ImmunityBio
10.38USD+0.92%Share
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and...
What's happening?
IBRX is outpacing Healthcare this month: +28.5% against +3.8% for the average Healthcare stock.
Above its 200-day average since 13 Jan · 24 of 34 Healthcare stocks are trending up.
- 1D
- +0.92%
- 7D
- +21.83%
- 1M
- +28.47%
- 3M
- +16.50%
- 6M
- +46.61%
- YTD
- +424.24%
What is the market expecting?
No forward P/E, as a loss is expected; analysts' mean target sits 25.2% above the price.
Not ranked on value: this stock carries too few of the multiples to score against its sector.
Is the business delivering?
Revenue +93.9% on a year ago; met or beat the estimate in 2 of the last 4 quarters.
Earnings by quarter
Latest quarter -230M · +402M on the quarter before · -138M on a year earlier
- -85.7MNov24+48.8M
- -59.2MMar25+26.6M
- -130MMay25-70.5M
- -92.6MAug25+37.1M
- -67.3MNov25+25.3M
- -61.9MFeb26+5.31M
- -633MMay26-571M
- -230MAug26+402M
Net income from the income statement, in USD, by the month it was reported.
How does it compare?
Value rankingIBRX is not ranked on value, so there are no nearest stocks to set it against.
What happens next?
Reports next on 3 Nov, in 29 days.
Fundamentals
On the shortlist
IBRX isn't in any strategy's Top Matches or Close Matches today.
In the briefing
Briefing for 5 OctThe briefing has not named IBRX.
Shortlist history
IBRX has not made the shortlist since the ledger opened.
Keep researching
Where next from IBRX
Daily market updates
Get the daily brief
Get an interesting stock pick, updates on the AI sector, information on the biggest movers of the day, and more, in the Monday to Saturday email.